Fidelity SPDR Advertisement
Home > Boards > Free Zone > Big Board Trading - Technical > *SCALPSWINGSTRADDLE* ($$$)

Pharmacyclics pullback a buying opportunity, says Credit Suisse

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
madrose1 Member Profile
Member Level 
Followed By 295
Posts 47,229
Boards Moderated 10
Alias Born 04/07/01
160x600 placeholder
Big Homes Can Complicate Retirement
Once you've paid for your house, how much will it cost you?
China Mobile's Need for Speed -- Barron's Asia
Intel Projects More Growth in 2015 -- Update
Zoetis Unveils $500 Million Stock Buyback Plan -- Update
Technip Bids for CGG -- 2nd Update
Appeals Court Grants TV Programmers Stay in FCC Dispute -- Update
Wireless Carriers Bid Up US Airwaves To Record
Two Top-Producing Advisers Leave Merrill Lynch--Street Moves
Chinese Premier Plays Down Qualcomm's Woes
Activision Blizzard to Get $275 Million in Settlement
madrose1 Member Level  Monday, 03/25/13 08:37:55 AM
Re: None
Post # of 649922 
Pharmacyclics pullback a buying opportunity, says Credit Suisse
Credit Suisse would use the pullback in Pharmacyclics as a buying opportunity given the multi-billion dollar potential of ibrutinib. Shares are Outperform rated with a $90 price target

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist